peppersite
Growth hormone axissubcutaneous

Tesamorelin / Ipamorelin

TesamorelinIpamorelin

This is a combination of two growth hormone compounds sold in a single vial: tesamorelin, a synthetic copy of growth hormone-releasing hormone, and ipamorelin, a ghrelin mimic that acts as a growth hormone secretagogue. It is sold for research use and is studied in the context of the growth hormone system, visceral fat and recovery.

A blend, not a compound

This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.

Researched for
Body CompositionMetabolic HealthRecoveryLongevity

At a glance

Also called
Tesamorelin + Ipamorelin
Type
Growth hormone axis
Given by
subcutaneous
Evidence
Not yet audited here; the reference library calls it emerging
Reported amount
Sources differ. See the source

How much to draw

Full calculator →
Your draw
–units
Fill in the three numbers to see the draw.
Amount per dose

The reference does not report a single injectable amount for Tesamorelin / Ipamorelin, so the amount is yours to enter. The arithmetic is the same for any vial. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Tesamorelin / Ipamorelin or for anything else, and nothing below has been checked against the study it came from.

Tesamorelin 1-2 mg + Ipamorelin 200-300 mcg (separate vials); or blend draws of 10-40 units/day depending on vial ratio (5/5 vial example: up to 667 mcg tesamorelin + 667 mcg ipamorelin at 40 units)
Frequency
Once daily subcutaneousStandard: 8-12 weeks on, 4-8 weeks off; Extended: 12-16 weeks on, 4-8 weeks off; typical cycle 8-16 weeks
Route
subcutaneous
Reported by
peptidedosingprotocols.com
What it says[Source: peptidedosingprotocols.com]
Reconstitution, as reported
  • Add 3.0 mL bacteriostatic water to the 3 mL vial, aiming the stream down the inside vial wall; swirl gently (do not shake) until fully dissolved. Inspect: solution should be clear; discard if cloudy or full of particles. Label with ratio, date, and concentration. Refrigerate at 2-8°C (35.6-46.4°F), protected from light. 10/3 vial yields ~4.33 mg/mL total (3.33 mg/mL tesamorelin + 1.0 mg/mL ipamorelin); 5/5 vial yields ~3.33 mg/mL total (1.67 mg/mL each). Do not freeze reconstituted solution.
Not yet audited

We have not published an audit on Tesamorelin / Ipamorelin. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

The two parts raise growth hormone through different doors into the same pituitary gland: tesamorelin copies the brain's growth hormone-releasing signal, while ipamorelin copies ghrelin and acts on a separate receptor, so together they feed one larger pulse. Researchers describe tesamorelin as binding GHRH receptors and ipamorelin as binding the GHS-R1a ghrelin receptor, with ipamorelin reported as selective for growth hormone and having little effect on cortisol or prolactin in animal studies. Pairing these two classes has produced larger growth hormone pulses than either alone in human secretagogue studies, but that synergy is shown for the classes in general and no human trial has tested this exact blend.

In technical termsCombines a GHRH analog (Tesamorelin) with a GH secretagogue (Ipamorelin) for GH-axis stimulation; studied for body composition and recovery.

Reported side effects

Seen in studies: from tesamorelin trials, the most commonly reported problems were reactions at the injection site such as redness and itching, joint pain, pain in the arms and legs, fluid retention and muscle aches. Tesamorelin has also been linked to glucose intolerance and a higher risk of type 2 diabetes. Ipamorelin is described as generally well tolerated in animal studies and the limited human data, with occasional passing flushing or headache.

Not ruled out: no human trial has characterized the side-effect profile of the blend itself. Raising growth hormone through both pathways could increase growth hormone-related effects such as water retention, joint discomfort or numbness and tingling, and because growth hormone lowers insulin sensitivity, blood sugar is a particular concern. Ipamorelin has not completed human trials, so its long-term safety is unestablished. Injection-site lumps can develop without rotating sites, and grey-market quality varies, so a current Certificate of Analysis for the exact batch is described as a check before use.

Who should avoid it

People who are pregnant: tesamorelin is contraindicated in pregnancy.

People with glucose intolerance or at risk of type 2 diabetes: tesamorelin has been linked to glucose intolerance and a higher risk of type 2 diabetes, and growth hormone lowers insulin sensitivity.

Anyone outside a research context: the blend is not FDA-approved, is sold for research use only, and is not intended for general use.

What gets monitored

Blood glucose monitoring is implied for anyone with glucose issues (GH lowers insulin sensitivity); a current Certificate of Analysis (COA) for the exact batch is recommended before use. An at-home blood test (SiPhox Health) is listed as a companion supply. (reported by peptidedosingprotocols.com)

Common questions

What is the tesamorelin and ipamorelin blend?

It is a combination of two growth hormone compounds in one vial: tesamorelin, a GHRH copy, and ipamorelin, a ghrelin-mimicking growth hormone secretagogue. They act on two different receptors that feed the same growth hormone pulse, and the blend is sold for research use only and is not FDA-approved as a combination product.

What amounts are reported for the blend?

Reported amounts and schedules for Tesamorelin / Ipamorelin differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

What is the difference between the 10/3 and 5/5 blend?

The 10/3 vial holds 10 mg of tesamorelin and 3 mg of ipamorelin, 13 mg in total, so it leans toward the GHRH side. The 5/5 vial holds 5 mg of each, 10 mg in total, for a balanced 1 to 1 ratio, and the ratio changes how much of each compound sits in every draw.

How is the blend reconstituted?

That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.

Why are tesamorelin and ipamorelin combined?

They are commonly paired in research planning because they act on two different growth hormone pathways, and GHRH-plus-secretagogue pairings have produced amplified growth hormone pulses in human secretagogue studies. No human trial has tested this specific blend, so its combined safety and effect profile is not established.

When is the blend usually taken in research planning?

Once-daily evening or bedtime timing is the most common structure described, chosen to track the body's natural nighttime growth hormone release. Some people using separate vials place ipamorelin earlier in the day. This is a planning convention, not a medical instruction.

How long is a typical cycle?

Research-planning cycles are commonly described as 8 to 16 weeks followed by 4 to 8 weeks off, a convention meant to limit receptor desensitization. There is no established cycle length for the blend itself.

Is the tesamorelin ipamorelin blend FDA-approved?

No. As of June 2026 tesamorelin is FDA-approved only for HIV-associated lipodystrophy, sold as EGRIFTA WR and EGRIFTA SV, ipamorelin is not FDA-approved, and the blend is not FDA-approved. It is sold for research use only.

Sources

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things
Sermorelin Acetate

Sermorelin is a lab-made peptide that copies the first 29 amino acids of the body's own growth hormone-releasing hormone (GHRH). It has been studied in the growth hormone system, including FDA-era trials as a diagnostic agent and as a treatment for growth hormone deficiency in children.

Glutathione

Glutathione (GSH) is a small molecule built from three amino acids, cysteine, glycine and glutamate, made by nearly every cell and most of all by the liver. It has been studied in people for skin lightening, liver enzymes in fatty liver disease, and Parkinson's disease.

MOTS-c

MOTS-c is a short chain of 16 amino acids that cells build from mitochondrial DNA rather than from the DNA in the nucleus. Most of what is known about it comes from cell and animal work on metabolism, exercise capacity and insulin sensitivity.

GHK-Cu

GHK-Cu, or copper tripeptide-1, is a natural peptide of three amino acids bound to a copper ion, found in human blood plasma. It is studied for skin, hair and wound repair, mostly in cells and animals, with the strongest human evidence for topical use.

Tirzepatide

Tirzepatide is a lab-made peptide that switches on two gut-hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is studied in people for weight management and blood sugar control, including in the SURPASS and SURMOUNT trial programs.

5-Amino-1MQ

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.